American Journal of Psychiatry· 2013Q1

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

James W. Murrough, Dan V. Iosifescu, Lee C. Chang, Rayan K. Al Jurdi et al.

1,210citations
Q1SCImago
2013year

Short summary

A single intravenous infusion of ketamine significantly improved depression symptoms by 7.95 points on the MADRS scale compared to midazolam at 24 hours in patients with treatment-resistant major depression (N=73).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pharmacology

PharmacologyMedicine